A new study has revealed that treatment with low-dose growth hormone improves abdominal fat and blood pressure measurements for HIV patients, but worsens glucose levels.
Dr. Steven Grinspoon and his colleagues at Massachusetts General Hospital in Boston say that they have studied the impact of growth hormone treatment on HIV patients with treatment-related abdominal obesity and growth hormone deficiency.
Human Growth Hormone
Human growth hormone, otherwise known as somatotropin, stimulates growth, cell reproduction, and bone regeneration.
Advertisement
They have revealed that the objective of the study was to determine whether low-dose GH in 56 HIV patients with abdominal fat accumulation and GH deficiency would improve body composition, lipids, and other metabolic and cardiovascular measures.
Fifty-five patients (26 with GH and 29 with placebo) were included in the safety analyses, and 52 patients (25 with GH and 27 with placebo) were included in the efficacy analyses.
![Acromegaly]( "Acromegaly")
Acromegaly (Greek-enlargements of the extremities) is a hormonal disorder resulting from excessive production of the growth hormone by the pituitary gland after puberty, often referred as gigantism.
The researchers found that abdominal fat decreased significantly in the GH group as against the placebo group, with a percentage change in the GH group of -8.5 percent and -1.6 percent in the placebo group.
Trunk-to-lower extremity fat ratio and trunk fat also decreased in the GH group compared with the placebo group.
Triglycerides and diastolic blood pressure (BP) levels improved with GH, while the change in systolic BP was not statistically different compared with placebo.
However, total cholesterol and high-density lipoprotein (HDL) cholesterol levels were unchanged between the two groups.
GH increased glucose levels during glucose tolerance testing, but long-term indices of glucose, hemoglobin A1c (the substance of red blood cells that carries oxygen to the cells and sometimes joins with glucose), were not different between the groups.
"Data from our randomized, placebo-controlled trial involving a long duration of observation inject a note of caution into the debate regarding the use of GH therapy in the HIV population," wrote the authors.
They added: "Low-dose physiological GH is well-tolerated and results in significant but more modest reduction in visceral adipose tissue [VAT; abdominal fat], but is nonetheless associated with increased glucose levels. Therefore, the therapeutic window to achieve an optimal risk-benefit ratio of GH in individuals with HIV, abdominal fat accumulation, and insulin resistance may be very narrow and difficult to achieve."
The findings were presented at a JAMA media briefing on HIV/AIDS, and have been published in the latest issue of JAMA.
Source: ANI
RAS/L
Acromegaly
Acromegaly (Greek-enlargements of the extremities) is a hormonal disorder resulting from excessive production of the growth hormone by the pituitary gland after puberty, often referred as gigantism.
Advertisement
The researchers found that abdominal fat decreased significantly in the GH group as against the placebo group, with a percentage change in the GH group of -8.5 percent and -1.6 percent in the placebo group.
Trunk-to-lower extremity fat ratio and trunk fat also decreased in the GH group compared with the placebo group.
Triglycerides and diastolic blood pressure (BP) levels improved with GH, while the change in systolic BP was not statistically different compared with placebo.
However, total cholesterol and high-density lipoprotein (HDL) cholesterol levels were unchanged between the two groups.
GH increased glucose levels during glucose tolerance testing, but long-term indices of glucose, hemoglobin A1c (the substance of red blood cells that carries oxygen to the cells and sometimes joins with glucose), were not different between the groups.
"Data from our randomized, placebo-controlled trial involving a long duration of observation inject a note of caution into the debate regarding the use of GH therapy in the HIV population," wrote the authors.
They added: "Low-dose physiological GH is well-tolerated and results in significant but more modest reduction in visceral adipose tissue [VAT; abdominal fat], but is nonetheless associated with increased glucose levels. Therefore, the therapeutic window to achieve an optimal risk-benefit ratio of GH in individuals with HIV, abdominal fat accumulation, and insulin resistance may be very narrow and difficult to achieve."
The findings were presented at a JAMA media briefing on HIV/AIDS, and have been published in the latest issue of JAMA.
Source: ANI
RAS/L
Agriculture's Environmental Impact Reduced If Cows are Supplemented With RbST
A new study has determined that cows that receive recombinant Bovine Somatotropin (rbST) make more milk, all the while easing natural resource pressure and substantially reducing environmental impact.
Advertisement
 Scientists Identify Potential Protein Biomarkers for Growth HormoneResearchers at Ohio University have identified several proteins in mice that might act as biomarkers for growth hormone. | Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
